Diltiazem

CAT: 804-HY-B0632-01Size: 100 mgDry Ice: NoHazardous: No
100 mgSelected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Diltiazem is an orally active L-type Ca2+ channel blocker. Diltiazem shows antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris[1][2][3].
CAS Number
[42399-41-7]
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Calcium Channel
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/diltiazem.html
Purity
99.70
Solubility
DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CN(C)CCN1C2=CC=CC=C2S[C@@H](C3=CC=C(OC)C=C3)[C@@H](OC(C)=O)C1=O
Molecular Formula
C22H26N2O4S
Molecular Weight
414.52
Precautions
H302, H315, H319
References & Citations
[1]Yoshinari Niimi, et al. Diltiazem facilitates inactivation of single L-type calcium channels in guinea pig ventricular myocytes. Jpn Heart J. 2003 Nov;44 (6) :1005-14.|[2]S Lin Tang, et l. Structural Basis for Diltiazem Block of a Voltage-Gated Ca2+ Channel. Mol Pharmacol. 2019 Oct; 96 (4) : 485-492.|[3]Anja Mieth , et al. L-type calcium channel inhibitor diltiazem prevents aneurysm formation by blood pressure-independent anti-inflammatory effects. Hypertension. 2013 Dec;62 (6) :1098-104.|[4]S. J. Downing, et al. Diltiazem pharmacokinetics in the rat and relationship between its serum concentration and uterine and cardiovascular effects. Br J Pharmacol. 1987 Aug; 91 (4) : 735-745.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
L-type calcium channel
Citation 01
ACS Environ Au. 2025 Aug 8.|Anal Chem. 2025 Jun 3;97 (21) :11099-11109.|J Cardiovasc Transl Res. 2023 Aug;16 (4) :758-767.|Nat Commun. 2024 Jun 19;15 (1) :5230.|Pharmacol Res Perspect. 2021 Oct;9 (5) :e00879.|medRxiv. 2025 May 21.|Pharmacol Res Perspect. 2020 Apr;8 (2) :e00575.|Vet Sci. 2025 Sep 5;12 (9) :864.|Virology. 2020 Jan 2;539:38-48.

Related Products

CatalogName